Amrutanjan Health Care Limited (BOM:590006)
India · Delayed Price · Currency is INR 638.00
-7.30 (-1.13%)
At close: Feb 12, 2026
Amrutanjan Health Care Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Operating Revenue | 4,882 | 4,518 | 4,212 | 3,796 | 4,058 | 3,328 |
Other Revenue | 1.47 | 1.47 | 1.41 | 1.23 | 1.06 | 1.69 |
| 4,883 | 4,520 | 4,214 | 3,798 | 4,059 | 3,330 | |
Revenue Growth (YoY) | 10.09% | 7.26% | 10.96% | -6.45% | 21.90% | 27.23% |
Cost of Revenue | 2,456 | 2,289 | 2,170 | 1,874 | 1,838 | 1,432 |
Gross Profit | 2,428 | 2,230 | 2,043 | 1,924 | 2,221 | 1,899 |
Selling, General & Admin | 669.69 | 597.16 | 484.02 | 492.2 | 484.84 | 420.53 |
Other Operating Expenses | 1,064 | 1,035 | 1,026 | 960 | 879.76 | 647.2 |
Operating Expenses | 1,797 | 1,698 | 1,571 | 1,505 | 1,423 | 1,181 |
Operating Income | 630.93 | 532.59 | 472.47 | 418.55 | 798.41 | 717.93 |
Interest Expense | -1.92 | -2.19 | -1.57 | -0.77 | -4.85 | -5 |
Interest & Investment Income | 160.47 | 160.47 | 148.05 | 117.83 | 111.7 | 93.88 |
Currency Exchange Gain (Loss) | 0.26 | 0.26 | 0.62 | 2.38 | 1.25 | 0.59 |
Other Non Operating Income (Expenses) | 0.03 | 0.19 | 0.69 | 0.24 | 0.83 | 0.42 |
EBT Excluding Unusual Items | 789.77 | 691.32 | 620.26 | 538.23 | 907.34 | 807.82 |
Gain (Loss) on Sale of Investments | 0.02 | 0.02 | -1.26 | -2.05 | -1.57 | -3.67 |
Gain (Loss) on Sale of Assets | - | - | 1.57 | 0.27 | - | 0.89 |
Asset Writedown | - | - | -1.11 | - | - | - |
Other Unusual Items | -12.52 | - | - | - | - | - |
Pretax Income | 777.27 | 691.34 | 619.46 | 536.45 | 905.77 | 819.05 |
Income Tax Expense | 208.25 | 182.99 | 169.73 | 138.11 | 233.88 | 207.14 |
Earnings From Continuing Operations | 569.03 | 508.35 | 449.73 | 398.35 | 671.89 | 611.9 |
Net Income | 569.03 | 508.35 | 449.73 | 398.35 | 671.89 | 611.9 |
Net Income to Common | 569.03 | 508.35 | 449.73 | 398.35 | 671.89 | 611.9 |
Net Income Growth | 15.38% | 13.04% | 12.90% | -40.71% | 9.80% | 143.95% |
Shares Outstanding (Basic) | 29 | 29 | 29 | 29 | 29 | 29 |
Shares Outstanding (Diluted) | 29 | 29 | 29 | 29 | 29 | 29 |
Shares Change (YoY) | -0.12% | -0.38% | -0.71% | -0.03% | 0.00% | 0.02% |
EPS (Basic) | 19.68 | 17.58 | 15.50 | 13.65 | 23.00 | 20.94 |
EPS (Diluted) | 19.68 | 17.58 | 15.50 | 13.63 | 22.98 | 20.93 |
EPS Growth | 15.50% | 13.44% | 13.70% | -40.69% | 9.79% | 143.94% |
Free Cash Flow | - | 153.46 | 211.93 | 112.54 | 287.32 | 889.09 |
Free Cash Flow Per Share | - | 5.31 | 7.30 | 3.85 | 9.83 | 30.41 |
Dividend Per Share | 4.600 | 4.600 | 4.600 | 4.600 | 4.600 | 4.200 |
Dividend Growth | - | - | - | - | 9.52% | 281.82% |
Gross Margin | 49.72% | 49.35% | 48.49% | 50.65% | 54.72% | 57.01% |
Operating Margin | 12.92% | 11.78% | 11.21% | 11.02% | 19.67% | 21.56% |
Profit Margin | 11.65% | 11.25% | 10.67% | 10.49% | 16.55% | 18.38% |
Free Cash Flow Margin | - | 3.40% | 5.03% | 2.96% | 7.08% | 26.70% |
EBITDA | 686.22 | 584.69 | 520.33 | 458.66 | 830.49 | 747.3 |
EBITDA Margin | 14.05% | 12.94% | 12.35% | 12.08% | 20.46% | 22.44% |
D&A For EBITDA | 55.29 | 52.1 | 47.86 | 40.11 | 32.09 | 29.37 |
EBIT | 630.93 | 532.59 | 472.47 | 418.55 | 798.41 | 717.93 |
EBIT Margin | 12.92% | 11.78% | 11.21% | 11.02% | 19.67% | 21.56% |
Effective Tax Rate | 26.79% | 26.47% | 27.40% | 25.74% | 25.82% | 25.29% |
Revenue as Reported | 5,059 | 4,695 | 4,376 | 3,942 | 4,212 | 3,442 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.